GlassScriptPhysician profile
Michael T Vercillo
NPI 1376767723
$3,768.92
in general payments reported to CMS, 2019-2025
21 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,486 · 2020: $49.34 · 2021: $320 · 2022: $608 · 2023: $351 · 2024: $645 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216 · Education: $90.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.73 |
| Education | $90.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micromed INC | $1,035.00 | 2019 | |
| Zimmer Biomet Holdings, INC. | $823.96 | 2019-2025 | Persona, Gel-One Cross-Linked Hyaluronate, Tapestry |
| Stryker Corporation | $406.96 | 2022-2025 | Mako, Triathlon, Hoffmann |
| Depuy Synthes Sales INC. | $232.52 | 2019-2025 | Orthovisc, Monovisc |
| Pacira Pharmaceuticals Incorporated | $216.44 | 2019-2024 | Exparel, Zilretta, Iovera |
| Bioventus LLC | $210.93 | 2022-2025 | Exogen Ultrasound Bone Healing System, Xcell, Durolane |
| Pacira Therapeutics, INC. | $153.39 | 2020-2021 | |
| Smith+Nephew, INC. | $153.27 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $145.38 | 2022 | |
| Linvatec Corporation | $96.52 | 2024 | Biobrace 23mm |
| Saxum Surgical, INC. | $47.62 | 2025 | |
| Sanofi-Aventis U.S. LLC | $46.67 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $33.18 | 2025 | |
| Horizon Therapeutics Plc | $32.44 | 2019 | |
| Ethicon US, LLC | $28.28 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.98 | 2024 | Proclaim |
| Innovation Technologies INC | $20.86 | 2021 | |
| Dynasplint Systems INC. | $18.62 | 2023 | Dynasplint |
| Vericel Corporation | $17.23 | 2019 | |
| Medtronic, INC. | $13.67 | 2024 | Plasmablade(Tm) |
| Assertio Therapeutics, INC. | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vercillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.